| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 51(1); 2019 > Article
Lee, Kang, Lim, Park, Park, Jung, Lee, Kang, Park, Park, Joo, Han, Kong, and Lee: Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers



The purpose of this study was to investigate decision patterns to reduce the risks of BRCArelated breast and gynecologic cancers in carriers of BRCA pathogenic variants. We found a change in risk-reducing (RR) management patterns after December 2012, when the National Health Insurance System (NHIS) of Korea began to pay for BRCA testing and riskreducing salpingo-oophorectomy (RRSO) in pathogenic-variant carriers.

Materials and Methods

The study group consisted of 992 patients, including 705 with breast cancer (BC), 23 with ovarian cancer (OC), 10 with both, and 254 relatives of high-risk patients who underwent BRCA testing at the National Cancer Center of Korea from January 2008 to December 2016.We analyzed patterns of and factors in RR management.


Of the 992 patients, 220 (22.2%) were carriers of BRCA pathogenic variants. About 92.3% (203/220) had a family history of BC and/or OC,which significantly differed between BRCA1 and BRCA2 carriers (p < 0.001). All 41 male carriers chose surveillance. Of the 179 female carriers, 59 of the 83 carriers (71.1%) with BC and the 39 of 79 unaffected carriers (49.4%) underwent RR management. None of the carriers affected with OC underwent RR management. Of the management types, RRSO had the highest rate (42.5%) of patient choice. The rate of RR surgery was significantly higher after 2013 than before 2013 (46.3% [74/160] vs. 31.6% [6/19], p < 0.001).


RRSO was the preferred management for carriers of BRCA pathogenic variants. The most important factors in treatment choice were NHIS reimbursement and/or the severity of illness.


Pathogenic variants of BRCA1 and BRCA2 result in hereditary breast-ovarian cancer syndrome (HBOS) in affected persons [1]. Activating mutations in BRCA1 and BRCA2 are present in approximately16%-25% of hereditary breast cancers (BCs) [2,3], 5%-10% of all BCs [4], and 15% of ovarian cancers (OC) [5]. BRCA pathogenic variants are also associated with an increased risk of developing any invasive cancer [6]. Risk-reducing mastectomy (RRM) reduces the lifetime risk of BC diagnosis [7]; and salpingo-oophorectomy is the single most effective method to prevent ovarian and fallopian tube cancer in women with a BRCA pathogenic variant [8,9]. Current National Comprehensive Cancer Network (NCCN) guidelines recommend risk-reducing salpingooophorectomy (RRSO) at age 35-45 years and after completion of child bearing. Patients who undergo RRM can select from various procedural options, each associated with a different risk of subsequently developing BC, and reconstruction options [10]. In Western countries, RRSO was the approach of choice to reduce the OC risk in about 50%-70% of patients with pathogenic variants of BRCA1 and BRCA2 undergoing risk-reducing (RR) management [3,11]. However, there are few reports about RR management in Asia. In December 2012, the National Health Insurance System (NHIS) of Korea approved reimbursement of BRCA testing and RRSO in patients suspected of having a BRCA1/2 mutation. The patterns of RR management began changing after NHIS instituted its new policy. However, RR management decision-making remains difficult because of various individual factors.
A recent retrospective study revealed that the rate of RRSO among female carriers of BRCA mutations in Korea was affected by the presence of amenorrhea and consultation with gynecologic oncologists [12]. To date, the types of RR management in Korean carriers of BRCA pathogenic variants, including unaffected pathogenic variant carriers, have not been evaluated. To address this gap in research, this study was designed to identify RR management patterns in Korean carriers of BRCA1 and BRCA2 pathogenic variants.

Materials and Methods

1. Study population

This study was designed as a retrospective cohort study. We evaluated the medical records of 992 consecutive patients, including those with breast and/or OC as well as relatives of high-risk patients, who underwent BRCA testing from January 2008 to December 2016 at the National Cancer Center of Korea (Goyang, Korea). Based on the standards of the National Medical Insurance Reimbursement in Korea, patients with BC and OC and a family history of BC or OC, early onset BC (diagnosed at age ≤ 40 years), bilateral BC, both BC and OC, male BC, or multi-organ cancer are recommended to undergo testing for BRCA1/2 pathogenic variants.

2. Genetic testing and RR management

BRCA mutations were determined by direct gene sequencing. Some patients without pathogenic variants who agreed to additional testing were further evaluated by BRCA deletion/duplication analysis using multiplex ligation-dependent probe amplification (MLPA) kits. Of the 992 individuals who underwent BRCA testing, 220 (22.2%) had BRCA pathogenic variants, including 125 (12.6%) with BRCA1 variants and 95 (9.6%) with BRCA2 variants (Fig. 1).
After patients with BRCA1/2 pathogenic variants were identified by genetic testing, the carriers met with a genetic counselor or various clinical experts, such as surgeons, oncologists specializing in BC, or gynecologic oncologists. Carriers were advised about appropriate risk reduction options according to carriers’ preference, disease severity, and expert advice on RR management.
RR management methods presented to carriers included RR surgery and chemoprevention. Chemoprevention included oral contraceptives, olaparib for patients with OC, and tamoxifen for hormone-receptor positive patients with BC. RR surgery included RRM and RRSO. For carriers who elected surveillance, BC and OC screening at 6-month intervals was recommended. Of the 220 BRCA pathogenic-variant carriers, 98 (44.5%) underwent RR management.

3. Statistical analysis

Statistical analysis was performed using SAS 9.4 software (SAS Institute Inc., Cary, NC). The distribution of clinicopathological characteristics in BRCA1 and BRCA2 pathogenic-variant carriers were compared, and the factors affecting RR management in the female carriers were assessed appropriately, depending on the characteristics of each variable. Male carrier patients were excluded from the analysis of RR management patterns. Continuous variables were analyzed using Student’s t test and represented as the mean±standard deviation, whereas categorical variables were analyzed using Pearson’s chi-square test or Fisher exact test, as appropriate, and represented as frequency and percentages. Statistical significance was defined as p < 0.05.

4. Ethical statement

The informed consent was waived and this study was approved by the Institutional Review Board of the Korean National Cancer Center (Goyang, Korea; approval no. NCC-2017-0219).


1. Comparison of BRCA1 vs. BRCA2

Of the 220 carriers of BRCA pathogenic variants, 125 had BRCA1 mutations, and 95 had BRCA2 mutations. Table 1 shows the clinical and pathological characteristics of these patients. The mean ages of these two groups were 39.3 and 43.7 years, respectively (p=0.009). The 220 carriers included 179 women and 41 men (p=0.100). None of these carriers had mutations in both the BRCA1 and BRCA2 genes.
The 220 individuals consisted of 83 patients with BC, 10 with OC, and seven with both, as well as 120 unaffected carriers (p=0.010). Approximately 92.3% (203/220) had a family history of BC and/or OC, including 117 (93.6%) of the 125 with BRCA1 mutations and 86 (90.5%) of the 95 with BRCA2 mutations (p < 0.001). The rate of family OC history was significantly higher (50.4% vs. 22.1%) and the rate of family BC history significantly lower (19.2% vs. 56.8%) in carriers of BRCA1 than in carriers of BRCA2 pathogenic variants. The rate of family BC history was also significantly lower in carriers of BRCA1 than in carriers of BRCA2 pathogenic variants with BC (44.4% vs. 78.7%, p=0.003). However, rates of early onset and bilateral BC, as well as stage of BC, did not differ significantly in carriers of BRCA1 and BRCA2 pathogenic variants. The most common BC subtypes in carriers of BRCA1 and BRCA2 mutations were basal-like (72.2% vs. 21.3%) and luminal A type (19.4% vs. 70.2%), respectively (p < 0.001). The percentages of carriers of BRCA1 and BRCA2 pathogenic variants did not differ significantly in patients with OC. In unaffected carriers of BRCA pathogenic variants, the rate of family BC history was significantly higher in carriers of BRCA2 than in carriers of BRCA1 pathogenic variants (3.9% vs. 39.5%), whereas the rate of familial OC history was significantly higher in BRCA1 than in BRCA2 variants (68.8% vs. 37.2%, p < 0.001).

2. RR management of female carriers of BRCA1/2 pathogenic variants

All 41 male carriers chose surveillance. RR management patterns in female carriers of BRCA1/2 pathogenic variants are presented in Fig. 2. Of these 179 women, 98 (54.7%) underwent RR management, including 18 (10.1%) who received chemoprevention and 80 (44.7%) who underwent risk-reducing surgery (RRS), including RRSO in 76 patients, RRM in one, and both in three. The remaining 81 patients (45.3%) chose intensive surveillance, including both BC and OC patients. Of the female BRCA1/2 pathogenic-variant carriers with BC, 59 (71.1%) underwent RR management, including RRSO in 53 patients, contralateral RRM in one, both in three, and chemoprevention in two (p=0.8497). The distribution of BC subtype in the 56 affected carriers with BC who underwent RRSO was 51.8% luminal A type, 7.1% luminal B type, 3.6% HER-2 type, and 37.5% basal type.
None of the affected carriers with OC underwent RR management for BC. Of the 79 unaffected female carriers, 39 (49.4%) received RR management, including 23 (29.1%) who underwent RRSO and 16 (20.3%) who received chemoprevention (p=0.495).
Insurance reimbursement started in 2013. The numbers of carriers of pathogenic variants detected (160 vs. 19) and the percentage who underwent RRS (46.3% [74/160] vs. 31.6% [6/19], p < 0.001) were significantly higher after 2013 than before 2013 (Fig. 2B).

3. Factors affecting RR management of female carriers of BRCA1/2 pathogenic variants

The type of female carriers was significantly associated with RR management (p < 0.001) (Table 2). In affected female carriers with BC, older age was significantly associated with RR management (p=0.011). However, in unaffected carriers, age, type of BRCA pathogenic variant, and family history were not significantly associated with RR management.


In the current study, we investigated RR management patterns in BRCA1 and BRCA2 pathogenic-variant carriers, including both affected and unaffected carriers. The prevalence of these pathogenic varinats was associated with both familial and personal factors. Carriers of pathogenic variants with both familial and personal factors were at much higher risk of cancer [13]. RR management in carriers of BRCA mutations has been studied more in Western than in Asian populations [3,14]. To our knowledge, this study involved the largest number of Asian BRCA pathogenic-variant carriers managed by RR approaches.
We found that older age of affected carriers with BC was significantly associated with RR management. Interestingly, in unaffected carriers, age, family history, and type of BRCA pathogenic variant were not associated with the decision to undergo RR management. The results showed that carriers may consider whether to undergo RR management differently depending on the type of carrier. Although a high percentage of BRCA carriers in a population-based health system underwent RRSO, these women did not undergo RRSO by the age recommended by the NCCN [14]. Older age was found to be significantly associated with an increase in RRSO rate [12]. According to the World Health Organization, the fertility rates of Korean women are lower than in other populations. As the average age at the first marriage increased in Korea, so has the age at the first childbirth. This may explain the association we found between age and decision to undergo RR management.
The prevalence of OC in our population was low. However, OC tends to be diagnosed at an advanced stage and has a poorer survival rate than BC [15]. Moreover, carriers of BRCA pathogenic variants were found to worry about developing OC [16,17]. Our findings were similar: the mean age of RR management in carriers with BC was 46 years, and the frequency of RR management was lower in patients with early onset BC. The rate of RRSO was higher in unaffected carriers with a family history of OC than in those with a familial history of BC. Assessment of survival in our population showed that four (4.8%) affected carriers with BC, one (10.0%) affected carrier with OC, and one (14.3%) affected carrier with both died. Most affected carriers with OC had advanced stage disease and were being treated with adjuvant chemotherapy. A review of pathologic reports of patients who underwent RR surgery showed that no woman who underwent RRM was diagnosed with BC, whereas three women who underwent RRSO were diagnosed with ovarian, fallopian tube, or peritoneal cancer and required additional treatment.
BC has a better prognosis than OC. BC screening is easier and can detect early cancerous lesions. With recent advancements, reconstructive surgery after mastectomy has a low rate of complications and increases patient satisfaction [18,19]. However, RRM may destroy body image and be costly, as it may not be reimbursed by insurance. A study of women carriers of BRCA pathogenic variants showed that those who opted for RRM were significantly more satisfied with their decision than those who did not undergo surgery [20]. A previous study showed RRM performed within 5 years was not cost effective when compared with BC screening for most BRCA pathogenic-variant carriers with OC [21]. Interestingly, we found that RRM was less preferred by these carriers, indicating that RRM must be chosen by patients.
In Korea, the detection of pathogenic variants and the performance of RRSs have changed over time. Since 2013, the annual number of individuals with BRCA pathogenic variants has increased, as has the percentage undergoing surgery. These increases are largely due to insurance reimbursement for RRSO and genetic testing of family members by the NHIS in Korea. Since October 2017, in carriers with BC, RRM of the contralateral breast and reconstruction are also covered. Future insurance coverage changes may further affect the patterns of RRSs in BRCA pathogenic-variant carriers. Another possible factor in the change of RR management patterns is the “Angelina Jolie effect” after the movie star Angelina Jolie, who is a BRCA pathogenic-variant carrier, underwent RRM despite being unaffected [22,23]. This increased public attention to HBOS and RR management [24]. In RR management, RRSO is a safe and simple surgery. Recently, embryonic natural orifice transumbilical endoscopic surgery is performed efficiently with good cosmetic outcome [25]. A meta-analysis of other studies on the efficacy of RRSO reported hazard ratios of 0.21 (95% confidence interval [CI], 0.12 to 0.39) for onset of ovarian and fallopian tube cancer and 0.49 (95% CI, 0.37 to 0.65) for onset of BC, indicating that the risk of developing these cancers was reduced following RRSO [26]. A third reason for the increase was the opening of genetic counseling clinics, with active counselors and researchers [27,28]. Our study showed that genetic testing and consulting have grown rapidly since 2013. Nevertheless, in this study, unaffected carriers paid less attention to RR management, with about 36% lost to followup. Decisions on RR management may depend on the various factors, including family history, awareness of disease, the individual’s environment, insurance reimbursement, and age at detection of a BRCA mutation [29]. Improved education and genetic counseling support throughout the decisionmaking process have been found to enhance carriers’ overall levels of satisfaction [30].
Our study had several limitations, despite assessing a greater number of patients with RR management than in previously published studies. First, this study was a single-center retrospective study. Second, we could not perform MLPA tests on all non-carriers of BRCA pathogenic variants. Third, this study examined a heterogeneous cohort. Future multicenter studies are needed to provide more information on patterns of RR management.
In this study, the older affected carriers with BC underwent more RR management, and RRSO was preferred to RRM by both affected carriers with BC and unaffected carriers. This may have been due to the severity of illness and to RRSO being the only RR strategy reimbursed by the NHIS. Further long-term follow-up prospective studies of RR management are needed, including investigations into the effects of genetic counseling, insurance payments, and social media marketing.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.


This study was supported by grants from the National Cancer Center of Korea (Nos. 1710171 & 1710172). We thank Kyungju Lee and Heesang Eum, who provided support for this study.

Fig. 1.
Flow diagram of study subjects. Genetic testing included direct sequencing and multiple ligation-dependent probe amplification analysis. A total of 220 carriers of pathogenic variants, including 125 with BRCA1 gene variants and 95 with BRCA2 gene variants, were identified.
Fig. 2.
Types of risk-reducing management applied to female BRCA1/2 pathogenic variant carriers over time. (A) Types of risk-reducing management chosen by affected female BRCA1/2 pathogenic-variant carriers with breast cancer and by unaffected carriers. (B) Numbers of women who underwent risk-reducing surgery before and after 2013, the year National Health Insurance System began reimbursing for BRCA testing and risk-reducing salpingo-oophorectomy in pathogenic-variant carriers. RRSO, riskreducing salpingo-oophorectomy; RRM, risk-reducing mastectomy.
Table 1.
Overall characteristics of BRCA pathogenic variant carriers
Clinicopathological characteristic Total BRCA1 BRCA2 p-value
BRCA pathogenic variant carriers 220 125 95
 Age (yr) 41.23±12.59 39.32±12.83 43.75±11.86 0.010
  Male 41 28 (22.4) 13 (13.7) 0.100
  Female 179 97 (77.6) 82 (86.3)
 Familial history
  None 17 8 (6.4) 9 (9.5) < 0.001
  Breast cancer 78 24 (19.2) 54 (56.8)
  Ovarian cancer 84 63 (50.4) 21 (22.1)
  Both breast and ovarian cancer 41 30 (24.0) 11 (11.6)
Affected carriers with breast cancer 83 36 47
 Age (yr) 45.01±8.92 43.78±8.61 45.96±9.14 0.273
 Familial history
  None 14 7 (19.4) 7 (14.9) 0.003
  Breast cancer 53 16 (44.4) 37 (78.7)
  Ovarian cancer 8 6 (16.7) 2 (4.3)
  Both breast and ovarian cancer 8 7 (19.4) 1 (2.1)
 Early onset breast cancer
  No 69 28 (77.8) 41 (87.2) 0.254
  Yes 14 8 (22.2) 6 (12.8)
 Bilaterality of breast cancer
  No 70 33 (91.7) 37 (78.7) 0.108
  Yes 13 3 (8.3) 10 (21.3)
 Stage of breast cancer
  Tis 3 2 (5.6) 1 (2.1) 0.602
  I 32 14 (38.9) 18 (38.3)
  II 41 16 (44.4) 25 (53.2)
  III 6 4 (11.1) 2 (4.3)
  IV 1 0 1 (2.1)
 Subtypes of breast cancer
  Luminal A 40 7 (19.4) 33 (70.2) < 0.001
  Luminal B 5 2 (5.6) 3 (6.4)
  HER2 2 1 (2.8) 1 (2.1)
  Basal 36 26 (72.2) 10 (21.3)
Affected carriers with ovary cancer 10 6 4
 Age (yr) 53±6.82 52.33±8.57 54±3.83 0.728
 Stage of ovarian cancer
  I 2 1 (16.7) 1 (25.0) 0.886
  II 2 1 (16.7) 1 (25.0)
  III 2 2 (33.3) 0
  IV 3 1 (16.7) 2 (50.0)
  Unknown 1 1 (16.7) 0
 Familial history
  None 2 0 2 (50.0) 0.333
  Breast cancer 1 1 (16.7) 0
  Ovarian cancer 5 3 (50.0) 2 (50.0)
  Both breast and ovarian cancer 2 2 (33.3) 0
Unaffected carriers 120 77 43
 Age (yr) 37±13.6 35.23±13.22 40.16±13.84 0.057
 Familial history
  Breast cancer 20 3 (3.9) 17 (39.5) < 0.001
  Ovarian cancer 70 53 (68.8) 16 (37.2)
  Both breast and ovarian cancer 30 21 (27.3) 9 (20.9)

Values are presented as the mean±standard deviation or the number (%).

Table 2.
Factors affecting risk-reducing management patterns in female BRCA1/2 pathogenic-variant carriers
Factor Total number Not performed RR management Performed RR management p-value
BRCA1/2 pathogenic variant carriers 179 81 98
 Age (yr) 43.15±12.26 43.58±13.32 42.79±11.37 0.667
BRCA mutation
  BRCA 1 97 47 (58.0) 50 (51.0) 0.349
  BRCA 2 82 34 (42.0) 48 (49.0)
 Type of carriers
  Affected carriers with breast cancer 83 24 (29.6) 59 (60.2) < 0.001
  Affected carriers with ovary cancer 10 10 (12.4) 0
  Affected carriers with both cancer 7 7 (8.6) 0
 Unaffected carriers 79 40 (49.4) 39 (39.8)
 Familial history
  None 17 8 (9.9) 9 (9.2) 0.249
  Breast cancer 72 27 (33.3) 45 (45.9)
  Ovarian cancer 60 33 (40.7) 27 (27.6)
  Both breast and ovarian cancer 30 13 (16.1) 17 (17.3)
Affected carriers with breast cancer 83 24 59
Age (yr) 45.01±8.92 41.13±7.80 46.59±8.93 0.011
Familial history
 None 14 5 (20.8) 9 (15.3) 0.853
 Breast cancer 53 14 (58.3) 39 (66.1)
 Ovarian cancer 8 3 (12.5) 5 (8.5)
 Both breast and ovarian cancer 8 2 (8.3) 6 (10.2)
Early onset breast cancer
 No 69 16 (66.7) 53 (89.8) 0.020
 Yes 14 8 (33.3) 6 (10.2)
Bilaterality of breast cancer
 No 70 21 (87.5) 49 (83.1) 0.748
 Yes 13 3 (12.5) 10 (17)
Stage of breast cancer
 Tis 3 0 3 (5.1) 0.489
 I 32 9 (37.5) 23 (39)
 II 41 13 (54.2) 28 (47.5)
 III 6 1 (4.2) 5 (8.5)
 IV 1 1 (4.2) 0
Subtypes of breast cancer
 Luminal A 40 11 (45.8) 29 (49.2) 0.930
 Luminal B 5 1 (4.2) 4 (6.8)
 HER2 2 0 2 (3.4)
 Basal 36 12 (50) 24 (40.7)
Unaffected carriers 79 40 39
 Age (yr) 39.14±14.56 41.20±16.34 37.03±12.33 0.205
 Familial history
  Breast cancer 14 8 (20.0) 6 (15.4) 0.659
  Ovarian cancer 46 24 (60.0) 22 (56.4)
  Both breast and ovarian cancer 19 8 (20.0) 11 (28.2)

Values are presented as the mean±standard deviation or the number (%). RR, risk-reducing.


1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318–24.
crossref pmid
2. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res. 1999;1:14–7.
crossref pmid pmc pdf
3. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13:51–6.
crossref pmid pmc
4. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008;124:31–42.
crossref pmid
5. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807–16.
crossref pmid
6. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005;7:60.

7. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–64.
crossref pmid
8. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011;204:19.
9. Morris JL, Gordon OK. Positive results: making the best decisions when you're at high risk for breast or ovarian cancer. Amherst, NY: Prometheus Books; 2010.

10. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, et al. Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. J Natl Compr Canc Netw. 2016;14:153–62.
crossref pmid
11. Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. 2012;118:510–7.
crossref pmid
12. Kim SI, Lim MC, Lee DO, Kong SY, Seo SS, Kang S, et al. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. J Cancer Res Clin Oncol. 2016;142:333–40.
crossref pmid pdf
13. Fu R, Harris EL, Helfand M, Nelson HD. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med. 2007;26:1775–87.
crossref pmid
14. Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132:428–33.
crossref pmid
15. Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, et al. Practice patterns of hereditary ovarian cancer management in Korea. Int J Gynecol Cancer. 2017;27:895–9.
crossref pmid
16. Lim MC, Moon EK, Shin A, Jung KW, Won YJ, Seo SS, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010. J Gynecol Oncol. 2013;24:298–302.
crossref pmid pmc
17. Watson M, Foster C, Eeles R, Eccles D, Ashley S, Davidson R, et al. Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer. 2004;91:1787–94.
crossref pmid pmc pdf
18. Del Corral GA, Wes AM, Fischer JP, Serletti JM, Wu LC. Outcomes and cost analysis in high-risk patients undergoing simultaneous free flap breast reconstruction and gynecologic procedures. Ann Plast Surg. 2015;75:534–8.
crossref pmid
19. Hagen AI, Maehle L, Veda N, Vetti HH, Stormorken A, Ludvigsen T, et al. Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers. Breast. 2014;23:38–43.
crossref pmid
20. Hooker GW, King L, Vanhusen L, Graves K, Peshkin BN, Isaacs C, et al. Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract. 2014;12:9.
crossref pmid pmc pdf
21. Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, et al. Cost effectiveness of risk-reducing mastectomy versus surveillance in BRCA mutation carriers with a history of ovarian cancer. Ann Surg Oncol. 2017;24:3116–23.
crossref pmid pmc pdf
22. Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16:442.
crossref pmid pmc pdf
23. Freedman R, Mountain H, Karina D, Schofield L. A retrospective exploration of the impact of the 'Angelina Jolie Effect' on the single state-wide familial cancer program in Perth, Western Australia. J Genet Couns. 2017;26:52–62.
crossref pmid pdf
24. Evans DG, Wisely J, Clancy T, Lalloo F, Wilson M, Johnson R, et al. Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. Breast Cancer Res. 2015;17:143.
crossref pmid pmc pdf
25. Lim MC, Kim TJ, Kang S, Bae DS, Park SY, Seo SS. Embryonic natural orifice transumbilical endoscopic surgery (E-NOTES) for adnexal tumors. Surg Endosc. 2009;23:2445–9.
crossref pmid
26. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.
crossref pmid pmc pdf
27. Bando H. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan. Breast Cancer. 2014;21:656–63.
crossref pmid
28. Eitan R, Michaelson-Cohen R, Levavi H, Beller U. The counseling and management of young healthy BRCA mutation carriers. Int J Gynecol Cancer. 2009;19:1156–9.
crossref pmid
29. Kauff ND, Scheuer L, Robson ME, Glogowski E, Kelly B, Barakat R, et al. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med. 2001;3:422–5.
crossref pmid
30. Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, et al. ASCO/SSO review of current role of riskreducing surgery in common hereditary cancer syndromes. Ann Surg Oncol. 2006;13:1296–321.
crossref pmid
PDF Links  PDF Links
PubReader  PubReader
ePub Link  ePub Link
XML Download  XML Download
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Web of Science
Related article
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI